Allergy Diagnostics & Therapeutics Market is anticipated to expand from $33.2 billion in 2024 to $60.7 billion by 2034, growing at a CAGR of approximately 6.2%. The global allergy diagnostics & therapeutics market is sizeable and growing steadily, driven by rising allergy prevalence, broader access to diagnostics, and expanded therapeutic options (including immunotherapies and biologics). Diagnostics (in-vitro and in-vivo testing) underpin appropriate treatment selection while therapeutics (antihistamines, corticosteroids, epinephrine, and allergen immunotherapies) capture the larger revenue share. Recent regulatory approvals and late-stage clinical activity in food allergy immunotherapies are intensifying commercial and clinical interest.
Request a Sample of this Report for Deeper Market Insights: https://www.globalinsightservices.com/request-sample/?id=GIS33607
Market dynamics:
Drivers
- Rising allergy prevalence & awareness: Urbanization, pollution, and longer pollen seasons increase incidence of allergic rhinitis, atopic dermatitis, asthma and food allergies — creating sustained diagnostic demand.
- Technological advances in diagnostics: Growth in automated singleplex (e.g., ImmunoCAP) and multiplex (microarray/component-resolved) tests improves speed, breadth, and clinical utility.
- Shift to disease-modifying therapies: Growth in allergen immunotherapy (subcutaneous, sublingual, epicutaneous) and development of targeted biologics for severe allergic disease drive therapeutics revenue and lifecycle opportunities.
Restraints & challenges
- Reimbursement variability: Inconsistent reimbursement for advanced diagnostics and immunotherapies across geographies limits uptake in some markets.
- Clinical complexity and adherence: Long treatment courses for immunotherapy and patient adherence issues (and safety monitoring requirements) constrain some adoption.
- Fragmented allergen landscape: Regional variation in relevant allergens complicates standardization of panels/consumables.
Opportunities
Food allergy immunotherapies: Late-stage clinical progress (e.g., epicutaneous patches) and regulatory momentum could open major new segments.
Point-of-care & multiplex testing: More comprehensive bedside and clinic testing can drive faster diagnosis and personalized treatment.
Emerging markets: Rising diagnosis rates in Asia Pacific and Latin America present volume opportunities for low-cost diagnostics and scalable treatment models.
Market Segmentation
| Type | In Vivo Allergy Diagnostics, In Vitro Allergy Diagnostics, Allergy Therapeutics |
| Product | Assay Kits, Instruments, Consumables, Reagents |
| Services | Consultation Services, Diagnostic Services, Therapeutic Services |
| Technology | ELISA, Immunoassay, Molecular Diagnostics, CRD (Component Resolved Diagnostics) |
| Application | Respiratory Allergies, Food Allergies, Drug Allergies, Skin Allergies |
| End User | Hospitals, Diagnostic Laboratories, Academic Research Institutes, Specialty Clinics |
| Device | Skin Prick Test Devices, Patch Test Devices, Blood Test Devices |
| Process | Sample Collection, Sample Analysis, Result Interpretation |
| Installation Type | Portable Devices, Stationary Devices |
| Solutions | Integrated Allergy Management Systems, Standalone Diagnostic Solutions |
Key Players
- Stallergenes Greer
- ALK-Abelló
- Anergis
- Circassia Pharmaceuticals
- Allergy Therapeutics
- HAL Allergy Group
- DBV Technologies
- Leti Pharma
- Abionic
- Inmunotek
- Diagenics
- Omega Diagnostics
- R-Biopharm
- Biomerica
- Bencard Allergie
Key players — in-depth analysis:
Thermo Fisher Scientific (Phadia / ImmunoCAP)
Strengths: Market leader in in-vitro allergy testing; broad allergen menu, high reproducibility; strong lab footprint and established customer base.
Focus: Expanding test availability, consumables revenue, and multiplex offerings. Recent product catalog updates and distribution expansion maintain leadership.
ALK-Abelló
Strengths: Global leader in allergen immunotherapy (both SCIT and SLIT). Strong regulatory track record.
Recent developments: European and Canadian approvals (and US FDA approvals/filings) for house-dust-mite SLIT/tablet products (ACARIZAX / ODACTRA approvals and filings across 2024–2025) — enhancing pediatric market access.
DBV Technologies
Strengths & innovation: Developer of epicutaneous immunotherapy (Viaskin) for peanut allergy — non-invasive, patch-based delivery with long-term data showing durable response in some cohorts.
Recent developments: Ongoing COMFORT toddler safety trial and regulatory interactions with FDA focused on a BLA pathway for younger children (activity in 2024–2025). Positive long-term data reported in 2025 publications.
Stallergenes Greer, Allergy Therapeutics plc and others
Profile: Strong regional presences, diverse product portfolios spanning SCIT/SLIT, niche allergen extracts, and services. Compete on regional formulations, partner networks, and payer relationships.
Regional analysis
North America: Mature market for diagnostics and symptomatic treatments. Increasing interest in food immunotherapies and biologics; strong reimbursement but regulatory scrutiny remains high.
Europe: Historically dominant in immunotherapy (regulatory support, higher uptake of SLIT/SCIT); home to major manufacturers (ALK, Stallergenes). Europe often leads in trial activity and approvals for immunotherapies.
Asia-Pacific & Latin America: Fastest volume growth potential due to rising diagnosis rates, urbanization, and improving healthcare access. Local manufacturers and low-cost diagnostics could capture share.
Recent news & notable developments:
ALK approvals / filings (house-dust-mite SLIT): ACARIZAX and ODACTRA approvals/filings in EU/Canada/US for pediatric indications (2024–2025) — important for pediatric market expansion.
DBV Technologies: Active clinical program (COMFORT toddler study) and regulatory interactions with FDA for VIASKIN peanut patch; ongoing data releases with multi-year outcomes supporting efficacy in some age groups. (2024–2025 updates).
Diagnostics expansions: Thermo Fisher continuing to expand ImmunoCAP availability and product catalog updates in 2024–2025, maintaining leadership in in-vitro allergy testing.
Browse Full Research Report: https://www.globalinsightservices.com/reports/allergy-diagnostics-therapeutics-market/
Strategic implications & recommendations
- Diagnostics providers: Expand multiplex/component panels and low-cost point-of-care offerings to capture early diagnosis in emerging markets and integrate with care pathways for immunotherapy.
- Therapeutics developers: Invest in pediatric indications and delivery platforms (epicutaneous, SLIT) and pursue robust long-term data to secure payer coverage. Regulatory momentum for pediatric immunotherapies creates near-term commercial opportunities (see ALK, DBV activity).
- Hospitals & clinics: Adopt standardized diagnostic algorithms (component testing where appropriate) to enable personalized therapy and improve adherence/monitoring.
- Investors & partners: Monitor late-stage food immunotherapy readouts and regulatory approvals—successful approvals may unlock material market expansion.
Scope of this report
Time frame: Baseline year references to 2023–2025 figures, forecasting trends through the end of the decade as cited by market research sources. (Most cited market figures use 2024/2025 as base years.)
Audience: Strategy teams, business development, investors, clinical lab leadership, product managers, and regulatory/medical affairs professionals in the allergy diagnostics & therapeutics ecosystem.
Limitations: Forecasts vary across vendors; I used multiple reputable market reports and primary company releases for triangulation. Local reimbursement and regulation details will materially affect country-level adoption and are beyond the scope of this high-level report.
Discover Additional Market Insights from Global Insight Services:
Allergy Diagnostics Market is anticipated to expand from $6.5 billion in 2024 to $13.2 billion by 2034, growing at a CAGR of approximately 7.3%.
Companion Animal Diagnostic Services Market is anticipated to expand from $7.19 billion in 2024 to $17.47 billion by 2034, growing at a CAGR of approximately 9.3%.
Self-testing Market is anticipated to expand from $14.1 billion in 2024 to $27.3 billion by 2034, growing at a CAGR of approximately 6.8%.
About Us:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes, DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/